1.80
-0.01(-0.55%)
Currency In USD
| Previous Close | 1.81 |
| Open | 1.78 |
| Day High | 1.86 |
| Day Low | 1.76 |
| 52-Week High | 8.33 |
| 52-Week Low | 1.5 |
| Volume | 1.94M |
| Average Volume | 1.33M |
| Market Cap | 162.99M |
| PE | -1.08 |
| EPS | -1.66 |
| Moving Average 50 Days | 2.08 |
| Moving Average 200 Days | 2.7 |
| Change | -0.01 |
If you invested $1000 in Caribou Biosciences, Inc. (CRBU) since IPO date, it would be worth $110.29 as of December 22, 2024 at a share price of $1.8. Whereas If you bought $1000 worth of Caribou Biosciences, Inc. (CRBU) shares 2 years ago, it would be worth $275.23 as of December 22, 2024 at a share price of $1.8.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Caribou Biosciences to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.
Nov 20, 2024 9:00 PM GMT
BERKELEY, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive of
Caribou Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire Inc.
Nov 06, 2024 9:05 PM GMT
-- Advancing four clinical-stage programs for hematologic malignancies and autoimmune diseases; multiple clinical data reports planned for 2025 -- -- Enrolling patients with LBCL (2L and after prior CD19-targeted therapies) with HLA matching strategy
Caribou Biosciences to Present Preclinical Data Supporting Development of CB-010 for Lupus at the American College of Rheumatology Convergence 2024
GlobeNewswire Inc.
Sep 25, 2024 1:00 PM GMT
BERKELEY, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced an abstract has been accepted for a poster presentation at the